Sugi Predict

Sugi Predict / Compounds / SCHEMBL4425824

SCHEMBL4425824

SCHEMBL4425824

CC(=O)OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](OC(C)=O)[C@@H]1OC(C)=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.65
▸ LMNA P02545 1/20 0.65
▸ TP53 P04637 1/20 0.65
▸ MAPT P10636 1/20 0.65
▸ TDP1 Q9NUW8 1/20 0.65
▸ PRKAB2 O43741 2/20 0.63
▸ PRKAG1 P54619 2/20 0.63
▸ PRKAA2 P54646 2/20 0.63
▸ PRKAA1 Q13131 2/20 0.63
▸ PRKAG3 Q9UGI9 2/20 0.63
▸ PRKAG2 Q9UGJ0 2/20 0.63
▸ PRKAB1 Q9Y478 2/20 0.63
▸ P2RX3 P56373 2/20 0.56
▸ P2RX4 Q99571 2/20 0.56
▸ P2RX2 Q9UBL9 2/20 0.56
▸ AHCY P23526 2/20 0.54
▸ MARS1 P56192 1/20 0.54
▸ ADORA1 P30542 4/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ DNPH1 O43598 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8205660 1.00 ALDH1A1 (0.65) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL31685764 1.00 ALDH1A1 (0.65) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL19889158 1.00 ALDH1A1 (0.65) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL11423681 1.00 ALDH1A1 (0.65) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL13597931 1.00 ALDH1A1 (0.65) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL23982402 1.00 ALDH1A1 (0.65) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL10033986 1.00 ALDH1A1 (0.65) ALDH1A1LMNATP53MAPTTDP1
SCHEMBL6744875 0.92 AHCY (0.59) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL10587115 0.92 AHCY (0.59) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL9300768 0.91 PRKAB2 (0.56) ALDH1A1LMNATP53MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12054768-B2 Methods for detecting agglutination and compositions for use in practicing the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-08-06 — — US disclosed
CN-117361680-A Preparation method and application method of organic matter extractant in wastewater 中钢集团鞍山热能研究院有限公司 2024-01-09 — — CN disclosed
US-11649222-B2 Compounds UNIVERSITETET I OSLO (NO) 2023-05-16 — — US disclosed
EP-4123031-A1 METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME The Regents of The University of California (US) 2023-01-25 — — EP disclosed
EP-3283638-B1 METHODS FOR DETECTING AGGLUTINATION AND USE OF KITS IN PRACTICING THE SAME UNIV CALIFORNIA (US) 2022-06-08 — — EP disclosed
US-20210403978-A1 METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-30 — — US disclosed
US-11149296-B2 Methods for detecting agglutination and compositions for use in practicing the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-10-19 — — US disclosed
US-20210221791-A1 COMPOUNDS UNIVERSITETET I OSLO (NO) 2021-07-22 — — US disclosed
US-10961223-B2 Compounds UNIVERSITETET I OSLO (NO) 2021-03-30 — — US disclosed
US-10584363-B2 Methods of producing and using single-stranded deoxyribonucleic acids and compositions for use in practicing the same TAKARA BIO USA, INC. (US) 2020-03-10 — — US disclosed
US-20080306076-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX, INC. (US) 2008-12-11 — — US disclosed
US-20040038373-A1 Apoptotic EBV-transformed lymphocytes, a therapeutic agent for post-transplant lymphoproliferative disorder PLATZ MATTHEW S (US) 2004-02-26 — — US disclosed
WO-2003054150-A2 APOPTOTIC EBV-TRANSFORMED LYMPHOCYTES, A THERAPEUTIC AGENT FOR POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2003-07-03 — — WO disclosed
US-5861503-A FLUORINATING WITH FLUORINE OR ACETYL HYPOFLUORITE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1999-01-19 — — US disclosed
EP-0683789-A1 N-ALKYL-2-SUBSTITUTED ATP ANALOGUES Astra Pharmaceuticals Limited (GB) 1995-11-29 — — EP disclosed
EP-0670845-A1 PROCESS FOR THE PREPARATION OF FLUDARABINE PHOSPHATE FROM GUANOSINE SCHERING AKTIENGESELLSCHAFT (DE) 1995-09-13 — — EP disclosed
WO-1994018216-A1 N-ALKYL-2-SUBSTITUTED ATP ANALOGUES ASTRA PHARMACEUTICALS LIMITED (GB) 1994-08-18 — — WO disclosed
WO-1994012514-A1 PROCESS FOR THE PREPARATION OF FLUDARABINE PHOSPHATE FROM GUANOSINE SCHERING AKTIENGESELLSCHAFT (DE) 1994-06-09 — — WO disclosed
US-4464361-A Adenosine derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-08-07 — — US disclosed
EP-0062921-A1 Adenosine derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1982-10-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306076-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH OR51E2, TAS2R50, TAS2R30 ALDH1A1 4103/4885LMNA 4624/4885TP53 2344/4885
US-11649222-B2 Compounds SLC30A6, SLC39A11, SLC39A3 ALDH1A1 3235/4885LMNA 1307/4885TP53 3509/4885
US-10961223-B2 Compounds SLC30A6, SLC39A11, SLC30A5 ALDH1A1 2991/4885LMNA 1309/4885TP53 3309/4885
US-20210221791-A1 COMPOUNDS SLC30A6, SLC30A5, SLC39A11 ALDH1A1 4328/4885LMNA 648/4885TP53 3650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.